Related Experiment Video
Updated: May 16, 2026
Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Neutrophils engraftment delay during tigecycline treatment in 2 bone marrow-transplanted patients
Natalia Maximova1, Davide Zanon, Federico Verzegnassi
1Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. maximova@burlo.trieste.it
Background:
Tigecycline is the first available drug of glycylcycline family. Because of recent introduction, some of its adverse effects could be still unexplored.
Observation:
We report the cases of 2 boys who underwent an allogenic bone marrow transplantation for acute myeloid leukemia and were treated with tigecycline. Erythrocyte and platelet engraftment followed a normal course, but the neutrophil count remained low despite the increase in leukocyte count. After tigecycline interruption, the neutrophil count rapidly raised in both cases.
Conclusions:
Neutropenia was suspected to be secondary to tigecycline exposure. In vitro experiments were performed, which suggested tigecycline influence on myeloid cells survival.
